List of Excipients in API rifaximin
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing rifaximin
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| A-S Medication Solutions | XIFAXAN | rifaximin | 50090-2445 | CELLULOSE, MICROCRYSTALLINE | 2027-09-02 |
| A-S Medication Solutions | XIFAXAN | rifaximin | 50090-2445 | EDETATE DISODIUM | 2027-09-02 |
| A-S Medication Solutions | XIFAXAN | rifaximin | 50090-2445 | FERRIC OXIDE RED | 2027-09-02 |
| A-S Medication Solutions | XIFAXAN | rifaximin | 50090-2445 | GLYCERYL PALMITOSTEARATE | 2027-09-02 |
| A-S Medication Solutions | XIFAXAN | rifaximin | 50090-2445 | HYPROMELLOSE | 2027-09-02 |
| A-S Medication Solutions | XIFAXAN | rifaximin | 50090-2445 | PROPYLENE GLYCOL | 2027-09-02 |
| A-S Medication Solutions | XIFAXAN | rifaximin | 50090-2445 | SILICON DIOXIDE | 2027-09-02 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for rifaximin
Excipient focus: CELLULOSE, MICROCRYSTALLINE
rifaximin drug variants containing CELLULOSE, MICROCRYSTALLINE
rifaximin drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: EDETATE DISODIUM
rifaximin drug variants containing EDETATE DISODIUM
| Company | Ingredient | NDC |
|---|---|---|
| A-S Medication Solutions | rifaximin | 50090-2445 |
| Physicians Total Care Inc | rifaximin | 54868-5972 |
| Salix Pharmaceuticals Inc | rifaximin | 65649-301 |
| Carilion Materials Management | rifaximin | 68151-4980 |
| Dispensing Solutions Inc | rifaximin | 68258-1107 |
| Avera McKennan Hospital | rifaximin | 69189-0309 |
| >Company | >Ingredient | >NDC |
rifaximin drug variants not containing EDETATE DISODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Cardinal Health 107 LLC | rifaximin | 55154-6777 |
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
rifaximin drug variants containing FERRIC OXIDE RED
rifaximin drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: GLYCERYL PALMITOSTEARATE
rifaximin drug variants containing GLYCERYL PALMITOSTEARATE
rifaximin drug variants not containing GLYCERYL PALMITOSTEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE
rifaximin drug variants containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| A-S Medication Solutions | rifaximin | 50090-2445 |
| Salix Pharmaceuticals Inc | rifaximin | 65649-301 |
| >Company | >Ingredient | >NDC |
rifaximin drug variants not containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| Physicians Total Care Inc | rifaximin | 54868-5972 |
| Cardinal Health 107 LLC | rifaximin | 55154-6777 |
| Carilion Materials Management | rifaximin | 68151-4980 |
| Dispensing Solutions Inc | rifaximin | 68258-1107 |
| Avera McKennan Hospital | rifaximin | 69189-0309 |
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSES
rifaximin drug variants containing HYPROMELLOSES
| Company | Ingredient | NDC |
|---|---|---|
| Physicians Total Care Inc | rifaximin | 54868-5972 |
| Carilion Materials Management | rifaximin | 68151-4980 |
| Dispensing Solutions Inc | rifaximin | 68258-1107 |
| Avera McKennan Hospital | rifaximin | 69189-0309 |
| >Company | >Ingredient | >NDC |
rifaximin drug variants not containing HYPROMELLOSES
| Company | Ingredient | NDC |
|---|---|---|
| A-S Medication Solutions | rifaximin | 50090-2445 |
| Cardinal Health 107 LLC | rifaximin | 55154-6777 |
| Salix Pharmaceuticals Inc | rifaximin | 65649-301 |
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL
rifaximin drug variants containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Cardinal Health 107 LLC | rifaximin | 55154-6777 |
| >Company | >Ingredient | >NDC |
rifaximin drug variants not containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| A-S Medication Solutions | rifaximin | 50090-2445 |
| Physicians Total Care Inc | rifaximin | 54868-5972 |
| Salix Pharmaceuticals Inc | rifaximin | 65649-301 |
| Carilion Materials Management | rifaximin | 68151-4980 |
| Dispensing Solutions Inc | rifaximin | 68258-1107 |
| Avera McKennan Hospital | rifaximin | 69189-0309 |
| >Company | >Ingredient | >NDC |
Excipient focus: POLYVINYL ALCOHOL
rifaximin drug variants containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Cardinal Health 107 LLC | rifaximin | 55154-6777 |
| >Company | >Ingredient | >NDC |
rifaximin drug variants not containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| A-S Medication Solutions | rifaximin | 50090-2445 |
| Physicians Total Care Inc | rifaximin | 54868-5972 |
| Salix Pharmaceuticals Inc | rifaximin | 65649-301 |
| Carilion Materials Management | rifaximin | 68151-4980 |
| Dispensing Solutions Inc | rifaximin | 68258-1107 |
| Avera McKennan Hospital | rifaximin | 69189-0309 |
| >Company | >Ingredient | >NDC |
Excipient focus: PROPYLENE GLYCOL
rifaximin drug variants containing PROPYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| A-S Medication Solutions | rifaximin | 50090-2445 |
| Physicians Total Care Inc | rifaximin | 54868-5972 |
| Salix Pharmaceuticals Inc | rifaximin | 65649-301 |
| Carilion Materials Management | rifaximin | 68151-4980 |
| Dispensing Solutions Inc | rifaximin | 68258-1107 |
| Avera McKennan Hospital | rifaximin | 69189-0309 |
| >Company | >Ingredient | >NDC |
rifaximin drug variants not containing PROPYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Cardinal Health 107 LLC | rifaximin | 55154-6777 |
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
rifaximin drug variants containing SILICON DIOXIDE
rifaximin drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM STARCH GLYCOLATE TYPE A POTATO
rifaximin drug variants containing SODIUM STARCH GLYCOLATE TYPE A POTATO
rifaximin drug variants not containing SODIUM STARCH GLYCOLATE TYPE A POTATO
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
rifaximin drug variants containing TALC
rifaximin drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
rifaximin drug variants containing TITANIUM DIOXIDE
rifaximin drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch